Talquetamab (Talvey)
Talvey is indicated: in combination with daratumumab and pomalidomide or in combination with daratumumab, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who… Show the full indication
Talvey is indicated: in combination with daratumumab and pomalidomide or in combination with daratumumab, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy. Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. Note: New text in bold CHMP post-authorisation summary of positive opinion for Talvey (VR-0000339914) Adopted Reference Number: EMADOC-1700519818-3395421 English (EN) (123.5 KB - PDF) First published: 16/10/2026 View Key facts Name of medicine Talvey EMA product number EMEA/H/C/005864 Active substance talquetamab International non-proprietary name (INN) or common name talquetamab Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutical chemical (ATC) code L01FX29 Additional monitoring This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicin
Interim analysis, phase 3, 864 patients with relapsed/refractory myeloma: talquetamab-daratumumab-pomalidomide and talquetamab-daratumumab both prolonged PFS vs daratumumab-pomalidomide-dexamethasone (HR 0.28 and 0.33). Serious adverse events 63.0%, 52.6%, 53.7%. RCT · phase 3 · n = 864 · N Engl J Med · 2026